Cargando…

Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes

An interagency collaboration was established to model chemical interactions that may cause adverse health effects when an exposure to a mixture of chemicals occurs. Many of these chemicals—drugs, pesticides, and environmental pollutant—interact at the level of metabolic biotransformations mediated b...

Descripción completa

Detalles Bibliográficos
Autores principales: McPhail, Brooks, Tie, Yunfeng, Hong, Huixiao, Pearce, Bruce A., Schnackenberg, Laura K., Ge, Weigong, Fuscoe, James C., Tong, Weida, Buzatu, Dan A., Wilkes, Jon G., Fowler, Bruce A., Demchuk, Eugene, Beger, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6268752/
https://www.ncbi.nlm.nih.gov/pubmed/22421792
http://dx.doi.org/10.3390/molecules17033383
_version_ 1783376358766804992
author McPhail, Brooks
Tie, Yunfeng
Hong, Huixiao
Pearce, Bruce A.
Schnackenberg, Laura K.
Ge, Weigong
Fuscoe, James C.
Tong, Weida
Buzatu, Dan A.
Wilkes, Jon G.
Fowler, Bruce A.
Demchuk, Eugene
Beger, Richard D.
author_facet McPhail, Brooks
Tie, Yunfeng
Hong, Huixiao
Pearce, Bruce A.
Schnackenberg, Laura K.
Ge, Weigong
Fuscoe, James C.
Tong, Weida
Buzatu, Dan A.
Wilkes, Jon G.
Fowler, Bruce A.
Demchuk, Eugene
Beger, Richard D.
author_sort McPhail, Brooks
collection PubMed
description An interagency collaboration was established to model chemical interactions that may cause adverse health effects when an exposure to a mixture of chemicals occurs. Many of these chemicals—drugs, pesticides, and environmental pollutant—interact at the level of metabolic biotransformations mediated by cytochrome P450 (CYP) enzymes. In the present work, spectral data-activity relationship (SDAR) and structure-activity relationship (SAR) approaches were used to develop machine-learning classifiers of inhibitors and non-inhibitors of the CYP3A4 and CYP2D6 isozymes. The models were built upon 602 reference pharmaceutical compounds whose interactions have been deduced from clinical data, and 100 additional chemicals that were used to evaluate model performance in an external validation (EV) test. SDAR is an innovative modeling approach that relies on discriminant analysis applied to binned nuclear magnetic resonance (NMR) spectral descriptors. In the present work, both 1D (13)C and 1D (15)N-NMR spectra were used together in a novel implementation of the SDAR technique. It was found that increasing the binning size of 1D (13)C-NMR and (15)N-NMR spectra caused an increase in the tenfold cross-validation (CV) performance in terms of both the rate of correct classification and sensitivity. The results of SDAR modeling were verified using SAR. For SAR modeling, a decision forest approach involving from 6 to 17 Mold(2) descriptors in a tree was used. Average rates of correct classification of SDAR and SAR models in a hundred CV tests were 60% and 61% for CYP3A4, and 62% and 70% for CYP2D6, respectively. The rates of correct classification of SDAR and SAR models in the EV test were 73% and 86% for CYP3A4, and 76% and 90% for CYP2D6, respectively. Thus, both SDAR and SAR methods demonstrated a comparable performance in modeling a large set of structurally diverse data. Based on unique NMR structural descriptors, the new SDAR modeling method complements the existing SAR techniques, providing an independent estimator that can increase confidence in a structure-activity assessment. When modeling was applied to hazardous environmental chemicals, it was found that up to 20% of them may be substrates and up to 10% of them may be inhibitors of the CYP3A4 and CYP2D6 isoforms. The developed models provide a rare opportunity for the environmental health branch of the public health service to extrapolate to hazardous chemicals directly from human clinical data. Therefore, the pharmacological and environmental health branches are both expected to benefit from these reported models.
format Online
Article
Text
id pubmed-6268752
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62687522018-12-20 Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes McPhail, Brooks Tie, Yunfeng Hong, Huixiao Pearce, Bruce A. Schnackenberg, Laura K. Ge, Weigong Fuscoe, James C. Tong, Weida Buzatu, Dan A. Wilkes, Jon G. Fowler, Bruce A. Demchuk, Eugene Beger, Richard D. Molecules Article An interagency collaboration was established to model chemical interactions that may cause adverse health effects when an exposure to a mixture of chemicals occurs. Many of these chemicals—drugs, pesticides, and environmental pollutant—interact at the level of metabolic biotransformations mediated by cytochrome P450 (CYP) enzymes. In the present work, spectral data-activity relationship (SDAR) and structure-activity relationship (SAR) approaches were used to develop machine-learning classifiers of inhibitors and non-inhibitors of the CYP3A4 and CYP2D6 isozymes. The models were built upon 602 reference pharmaceutical compounds whose interactions have been deduced from clinical data, and 100 additional chemicals that were used to evaluate model performance in an external validation (EV) test. SDAR is an innovative modeling approach that relies on discriminant analysis applied to binned nuclear magnetic resonance (NMR) spectral descriptors. In the present work, both 1D (13)C and 1D (15)N-NMR spectra were used together in a novel implementation of the SDAR technique. It was found that increasing the binning size of 1D (13)C-NMR and (15)N-NMR spectra caused an increase in the tenfold cross-validation (CV) performance in terms of both the rate of correct classification and sensitivity. The results of SDAR modeling were verified using SAR. For SAR modeling, a decision forest approach involving from 6 to 17 Mold(2) descriptors in a tree was used. Average rates of correct classification of SDAR and SAR models in a hundred CV tests were 60% and 61% for CYP3A4, and 62% and 70% for CYP2D6, respectively. The rates of correct classification of SDAR and SAR models in the EV test were 73% and 86% for CYP3A4, and 76% and 90% for CYP2D6, respectively. Thus, both SDAR and SAR methods demonstrated a comparable performance in modeling a large set of structurally diverse data. Based on unique NMR structural descriptors, the new SDAR modeling method complements the existing SAR techniques, providing an independent estimator that can increase confidence in a structure-activity assessment. When modeling was applied to hazardous environmental chemicals, it was found that up to 20% of them may be substrates and up to 10% of them may be inhibitors of the CYP3A4 and CYP2D6 isoforms. The developed models provide a rare opportunity for the environmental health branch of the public health service to extrapolate to hazardous chemicals directly from human clinical data. Therefore, the pharmacological and environmental health branches are both expected to benefit from these reported models. MDPI 2012-03-15 /pmc/articles/PMC6268752/ /pubmed/22421792 http://dx.doi.org/10.3390/molecules17033383 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
McPhail, Brooks
Tie, Yunfeng
Hong, Huixiao
Pearce, Bruce A.
Schnackenberg, Laura K.
Ge, Weigong
Fuscoe, James C.
Tong, Weida
Buzatu, Dan A.
Wilkes, Jon G.
Fowler, Bruce A.
Demchuk, Eugene
Beger, Richard D.
Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes
title Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes
title_full Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes
title_fullStr Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes
title_full_unstemmed Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes
title_short Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes
title_sort modeling chemical interaction profiles: i. spectral data-activity relationship and structure-activity relationship models for inhibitors and non-inhibitors of cytochrome p450 cyp3a4 and cyp2d6 isozymes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6268752/
https://www.ncbi.nlm.nih.gov/pubmed/22421792
http://dx.doi.org/10.3390/molecules17033383
work_keys_str_mv AT mcphailbrooks modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT tieyunfeng modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT honghuixiao modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT pearcebrucea modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT schnackenberglaurak modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT geweigong modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT fuscoejamesc modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT tongweida modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT buzatudana modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT wilkesjong modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT fowlerbrucea modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT demchukeugene modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes
AT begerrichardd modelingchemicalinteractionprofilesispectraldataactivityrelationshipandstructureactivityrelationshipmodelsforinhibitorsandnoninhibitorsofcytochromep450cyp3a4andcyp2d6isozymes